NEW
Pre-eclampsia Screening Antenatal
Bloods from 20 weeks
Pre-eclampsia is a serious complication in pregnancy which affects
both the mother and unborn child. It is defined as
pregnancy-induced hypertension and proteinuria. It is well
recognised, and is a major cause of maternal, fetal and neonatal
morbidity and mortality. The disorder develops early in the first
trimester. Pre-eclampsia and eclampsia may occur in as many as 8%
of pregnancies and the most recent official report from the UK
Centre for Maternal and Child Enquiries (CMACE 2011) ranked PE as
the second most common direct cause of maternal death, accounting
for around 18% of direct maternal deaths between 2006-2008.
This screening test allows for targeted perinatal care, risk
stratification and clinical benefit for earlier management of
pre-eclampsia.
Placental Growth Factor (PlGF) is the most discriminating
biochemical marker for pre-eclampsia and especially for early onset
pre-eclampsia. Levels of sFIT-1/PIGF are determined in parallel and
the sFlt-1/PIGF ratio are calculated. The ratio has been shown to
be a better predictor of PE than either measure alone. The Roche
sFlt-1/PIGF ratio allow for confirmation of pre-eclampsia with a
sensitivity of 82% and a specificity of 95% at a cut-off of 85.
This assay is validated for pre-eclampsia testing from 20 weeks
gestation.
|
Test |
Code |
Sample
Type |
Turnaround Time |
| Pre-Eclampsia
Screen |
PET |
 |
1 day
|